Kornimate/medical-research-clean huggingface dataset:
quantitative ultrasound assessment of abdominal cavity space

Conditions: Sepsis; MODS; Shock

Summary: this is a prospective observational study to observe the diagnostic efficacy of a quantitative ultrasound assessment plan for pathological accumulation in the abdominal cavity space of critically ill patients, and to explore its correlation with patient clinical outcomes.

intra-abdominal lesions, such as hemorrhage and inflammation/infection, often lead to pathological accumulations, posing serious challenges for critically ill patients. these lesions can rapidly induce intra-abdominal hypertension and organ damage, which may progress to hemorrhagic or septic shock, endangering patients\&#39; lives. intra-abdominal hemorrhage, especially surgery-related hemorrhage, is difficult to detect early, and existing assessment methods like ct scans have limited applicability in critically ill patients. intra-abdominal infections account for a high proportion of infections in critically ill patients, with concurrent sepsis or shock having high mortality rates. despite advancements in critical care medicine, the mortality rate from intra-abdominal infections remains stubbornly high. accurate assessment of the source and extent of infection is crucial for treatment, yet routine physical examinations have low sensitivity in critically ill patients, making imaging examinations the primary method. however, while abdominal ct is considered the gold standard, it is limited by insufficient dynamic monitoring and difficulties in patient transport. bedside ultrasound plays a significant role in the monitoring of critically ill patients due to its portability, non-invasiveness, and real-time dynamic capabilities. it can assess sources of hemorrhage and infection, quantify the extent of lesions, and monitor hemodynamic changes. therefore, this study aims to develop a comprehensive ultrasound assessment protocol that covers the peritoneal cavity and posterior peritoneal space. through a prospective observational study, we aim to validate its sensitivity and specificity in diagnosing pathological accumulations such as intra-abdominal hemorrhage/infection and explore its correlation with patient clinical outcomes.

Eligibility criteria:
inclusion criteria: * age \&gt; 18 years old; * expected icu stay ≥ 72 hours; * meeting one of the diagnostic criteria for intra-abdominal infection: 1) single organ infection (such as cholecystitis, appendicitis, diverticulitis, cholangitis, pancreatitis, salpingitis, etc.), which may be accompanied by or without peritonitis, even without perforation; 2) peritonitis, classified as primary, secondary, or recurrent; 3) intra-abdominal abscess. exclusion criteria: * patients with wounds, redness, swelling, bleeding, or other conditions at the abdominal measurement points that prevent ultrasound assessment; * patients with intra-abdominal gas accumulation that affects abdominal ultrasound imaging, making ultrasound quantitative scoring impossible; * patients who have not undergone abdominal ct examination within 72 hours of icu admission; * patients who do not consent to participate in this study.
the sense of agency

Conditions: Motor Activity; Motor Tic Disorders

Summary: the ability to recognize of being the actors of the behaviour and its consequences, the so-called "sense of agency" (soa), is a crucial component of self-awareness. one key aspect is the distinction from a mere inference about the causality between an act and its consequences and the sense of being the agent of it. despite a large number of behavioural studies, there is unsatisfactory evidence on the functional anatomical underpinnings of the soa and the distinction between causality and the soa proper. here, the investigators use an implicit measurement of the soa and its modulations during fmri: the intentional binding phenomenon (ib). the ivestigators also study how the soa and the ensuing neurophysiological correlates are modulated by the presence of a movement disorders, such as gilles de la tourette syndrome.


Eligibility criteria:
inclusion criteria: * age included between 18 and 65 years * right handed * no contraindication to the fmri exam exclusion criteria: * contraindication to the fmri exam
radicle health1: a study of health and wellness formulations and their effects on overall health

Conditions: Sleep; Pain; Depression; Anxiety

Summary: a randomized, blinded, placebo-controlled study of health and wellness product formulations and their effects on overall health

this is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the united states. eligible participants will (1) endorse a desire for better health during screening; (2) indicate an interest in taking a health and wellness product to potentially help improve their health, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. those taking certain medications will be excluded. self-reported data will be collected electronically from eligible participants over 5 weeks. participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. all study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Eligibility criteria:
inclusion criteria: * 21 years of age and older * resides in the united states * endorses: a desire for better sleep and/or focus, less pain, less feelings of stress, depression, and/or anxiety, and/or more energy (less fatigue) * expresses a willingness to take a study product that may contain cannabinoids (or placebo) and not know the product identity until the end of the study exclusion criteria: * reports being pregnant, trying to become pregnant, or breastfeeding * unable to provide a valid physical shipping address and mobile phone number * reports a diagnosis of liver or kidney disease * reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * reports current enrollment in a clinical trial * the qol score greater than 5 during enrollment * unable to read and understand english * lack of reliable daily access to the internet * reports taking any medication that warns against grapefruit consumption * reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection
a study in north macedonia investigating retrospective data of glucagon-like peptide-1 (glp-1) participants with type 2 diabetes (t2d) in real world environment (rwe) setting (mirage)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to investigate glycaemic control and other clinical parameters in glucagon like peptide -1 (glp-1) naive adult participants with type 2 diabetes (t2d) who initiated once weekly (ow) semaglutide in local clinical practice in north macedonia. the participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion. the total duration of the study is planned to be approximately 30 weeks which is the period from ow semaglutide initiation to end of follow up.


Eligibility criteria:
inclusion criteria: * male or female, age above or equal to 18 years at the time of once weekly (ow) semaglutide initiation. * the decision to initiate treatment with commercially available ow semaglutide has been made by the participant and the treating physician before and independently from the decision to include the participant in this study. * adult participants with type 2 diabetes (t2d) initiated with ow semaglutide at least 30 +- 4 weeks prior to data collection. * participants should have baseline glycated haemoglobin (hba1c) measurement and at least one hba1c measurement after baseline. for baseline hba1c measurement, the most recent value less than 12 weeks prior to ow semaglutide initiation will be used. exclusion criteria: * previous participation in this study. * prior use of glp-1 within last one year. * participants with type-1 diabetes and gestational diabetes.
paediatric chronic tracheostomy care: an evaluation of an innovative competency-based education program for community health care providers

Conditions: Evaluation of HomeCare RN Respiratory Education

Summary: this project will evaluate a new course developed for nurses that provide care to children with breathing technology including breathing tubes and home breathing machines. the investigators plan to assess the nurses' knowledge and comfort of their ability to care for these medical technologies prior to the course as well as their ability to retain their knowledge 6 weeks and 6 months after course completion.

a structured program evaluation considering a hierarchy of outcomes is essential to determine whether the tracheostomy module is associated with improved knowledge and skills for chps (community health providers). this investigators proposed study is guided by the evaluation of knowledge acquisition and self-efficacy as a theoretical framework 24. chps' sense of self-efficacy or perceived capability in caring for this population is important to foster to potentially mitigate significant morbidity and mortality, while ultimately striving for safe, high-quality clinical care for these medically complex children.

Eligibility criteria:
inclusion criteria: * course registrants for the competency-based tracheostomy education course from vha home healthcare agency * consent to study participation * english speaking exclusion criteria: • previously attended the competency-based tracheostomy course at sickkids
establishment and application of endometrial 3d-organoid in endometrial injury repair

Conditions: Asherman Syndrome

Summary: normal endometrial repair occurs without scar formation; however, in some women, these normal repair mechanisms are aberrant, resulting in intrauterine adhesion (iua) formation. intrauterine adhesion (iua) is one of the common causes of secondary infertility, accounting for approximately 8% of disease etiologies while the pathogenesis of iua remains unclear. organoids derived from iua endometrium can be used as excellent models to study iua due to genetically stable passage and the characteristics of simulating the microenvironment of the uterine cavity.

intrauterine adhesion (iua), also known as asherman syndrome, is a common gynecological disease, the main clinical manifestations are oligomenorrhea, amenorrhea, recurrent miscarriage and infertility, which seriously endanger the reproductive function of women of childbearing age . trauma and infection are the most common and important causes of iua. at present, the incidence of infertility in the population is about 9%-18%. according to the prediction of world health organization (who), iua will become the third largest disease after tumor and cardiovascular disease in the future. organoids are 3d self-organized structures that could derived from tissue and have a variety types of cell, and mimic the target organ in structure and function. they have the ability to proliferate, differentiate and self-renew. maintain genetic stability and reproduce some physiological functions. organoids forms closer intercellular connections and biological communication than 2d cultured cells, and is better used to simulate the occurrence process and physiological and pathological states of organs and tissues. therefore, investigator proposed to establish a iua organoids bio-bank for further investigation of pathogenesis of iua and seek for personalized therapy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of iua * undergoing hysteroscopic surgery for treatment exclusion criteria: ·receiving sex hormone therapy in the three months before surgery

Keywords: organoid asherman syndrome intrauterine adhesion
personalised cognitive remediation therapy (pcrt)

Conditions: Schizophrenia Schizoaffective

Summary: cognitive deficits have been shown to have negative impact on social functioning and functional goals such as ability to work and perform daily tasks in people with schizophrenia. there is evidence that cognitive remediation therapy, a form of psychological therapy, is effective in improving cognition and functioning but there is still a limited understanding of what influence people's different response to this therapy. a tailored treatment is likely to be more effective because it will adapt to service users' unique characteristics. the investigators are planning a study exploring at the feasibility and acceptability of novel form of cognitive remediation therapy which is personalised (pcrt) to the person individual characteristics. the personalised therapy will consist of task practice using computerized cognitive remediation software (i.e. called circuits). the knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.

cognitive deficits in people with psychosis have been shown to have negative impact on functional goals including the ability to work and perform daily tasks. cognitive remediation therapy (crt) is a psychological therapy developed to improve cognitive functions in people with schizophrenia but ultimately with a focus on improving social and functional outcomes. there is evidence that crt is effective in improving cognition and functioning but there is still a limited understanding of the mechanisms responsible for different treatment responses. this study attempts to fill this gap by developing and testing a new form of crt, which will personalise therapy elements according to participants' characteristics. the therapy will consist of task practice using a computerised cognitive remediation software and supervised activities supported by a therapist to boost functioning. the knowledge gathered in this work will contribute to develop the next generation of personalised treatment approaches for people with schizophrenia.

Eligibility criteria:
inclusion criteria: * a range of 18-65 years * english speaking or with a good knowledge of the language * a diagnosis of schizophrenia or schizoaffective disorder according to the dsm- v * at least one year contact with mental health services, * a deficit (of at least one standard deviation below the mean) in at least one cognitive domain out of these three cognitive domains: memory, executive function and information processing. exclusion criteria: * planned medication change * diagnosis of learning disability * presence of cognitive deficits related to organic causes or head injury * primary diagnosis of substance dependence

Keywords: cognitive remediation therapy crt
study to determine the antibody response to 500µg g17dt in treatment of patients with gastric cancer

Conditions: Gastric Cancer

Summary: this study was designed to investigate the antibody response generated by a 500µg dose of g17dt in patients with gastric cancer.

another study, gc2, initiated prior to the start of this study investigated the appropriate dose and dosing schedule for g17dt in patients with stage i-iii gastric cancer. the highest dose tested in the gc2 study was 250µg. this dose was well tolerated but was not considered sufficiently immunogenic. since tolerability had not constrained dosing up to 250µg, the gc5 study was designed to investigate a 500µg dose administered as a regimen of 0, 2, and 6 weeks.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed uicc stage i, ii or iii gastric adenocarcinoma. * patients must have had a macroscopically curative resection for gastric cancer with absence of metastatic disease at the time of entry to the trial. * male or female patients aged 18 years or older. * life expectancy of at least 3 months. * who performance status of 0 to 1. * written informed consent exclusion criteria: * gastric surgery within four weeks of baseline (week 0, visit 2) or gastric surgery anticipated during the period of the study. * history of other malignant disease within the previous five years, except nonmelanomatous skin cancer or in situ carcinoma of the uterine cervix. * previous use within the last four weeks, concomitant use of anticipated use in the period of study, of any anti-cancer therapies. * concomitant use of immunosuppressants, including systemic (i.e. oral or injected) corticosteroids. * females who were pregnant, planning to become pregnant or lactating. * patients taking part in another study involving an investigational or licensed drug or device in the three months preceding enrollment or during this study. * previous g17dt treatment. * haematologicial indicators: haemoglobin (hb) \< 10g/dl white blood cell count (wbc) \< 4.0 x 10\^9/l platelets \< 100 x 10\^9/l
effectiveness of microcurrent for treatment of tennis elbow

Conditions: Tennis Elbow

Summary: tennis elbow is a relatively common musculoskeletal disorder that can cause significant pain and disability. treatment of the disorder is not always successful, and it often recurs or becomes chronic. more effective management options are required. there is evidence that electric microcurrent can promote tissue healing and symptom resolution in various chronic hard and soft tissue disorders, but few human studies investigating its use with chronic tendon problems. it is an easily applied therapy with very few reports of side effects. it can be applied at home using a portable unit and, if it is clinically effective, may also prove more cost effective than other therapies. a clinical trial is planned to evaluate the therapy but, in the absence of relevant published evidence, a preliminary study is required to look for a treatment effect and inform a power calculation for sample size, the study will also allow some investigation of dose-dependence, which is a key issue in many forms of electrotherapy. finally it will enable evaluation of elements of the full trial protocol so that any weaknesses can be addressed before it begins.


Eligibility criteria:
inclusion criteria: * symptoms of tennis elbow for at least 3 months * clinical diagnosis of tennis elbow exclusion criteria: * significant symptom improvement in previous month * receipt of any active treatment for the condition in the previous month * currently under the care of another health professional for tennis elbow * current cervical radiculopathy * other pathology affecting distal upper limb

Keywords: tennis elbow microcurrent tissue healing
prospective observational study of disease progression in chronic hepatitis c

Conditions: Hepatitis C, Chronic; Disease Progression; Liver Cirrhosis

Summary: the purpose of this study is to determine the progression of chronic hepatitis c patients infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease progression in chronic hepatitis c.


Eligibility criteria:
inclusion criteria: * all these patients had a definite history of regular plasma donations with repeated blood cell re-transfusions. * the hepatitis c virus antibody was positive. * all patients did not receive interferon therapy before being recruited. exclusion criteria: * patients with evidences for other forms of liver diseases. * the coinfection with hepatitis b virus or other virus.
lipopolysaccharide binding protein and development of infectious events in cirrhotic patients

Conditions: Cirrhosis; Ascites; Infections

Summary: the purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (lbp) are correlated with pbmn pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. as a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on lbp, cytokines and infections in the same patients.


Eligibility criteria:
inclusion criteria: * cirrhosis * ascites * no history of spontaneous bacterial peritonitis and/or \< 1 g of protein in ascites * no antibiotic use in previous 6 weeks * absence of infection (documented by clinical history, blood cytology, urinalysis and urine culture, thorax x-ray and paracentesis) * absence of gi bleeding or encephalopathy * signature of informed consent exclusion criteria: * ciprofloxacin contraindication * autoimmune hepatitis, sclerosing cholangitis or other autoimmune disease * \> 13 child-pugh points * inability to attend to regular visits * current alcohol intake * terminal disease with \< 24 week expected survival

Keywords: cirrhosis ascites lipopolysaccharide binding protein infections cytokines ciprofloxacin
compassionate use program for olipudase alfa enzyme replacement therapy for patients with chronic acid sphingomyelinase deficiency (asmd)

Conditions: Sphingomyelin Lipidosis

Summary: the objective of this program is to provide access to enzyme replacement therapy (ert) with olipudase alfa for certain patients with asmd, a severe, life threatening disease, that could not participate in the olipudase clinical trials. the program will provide access to olipudase alfa prior to registration and the availability of commercial product (including reimbursement where applicable) in the country of the patient.


Eligibility criteria:
inclusion criteria: all patients (adult and pediatric) * unsolicited request for the patient from a site with at least 3 years of experience in administration and safety management of ert. * written informed consent signed by the patient or the patient's parent(s)/guardian(s), where applicable. * documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts. adult patients * age ≥ 18 years. * clinically documented advanced disease evidenced by defined thresholds for lung, spleen, liver, and hematologic parameters. pediatric patients - age \>3 years and \<18 years or clinical diagnosis consistent with asmd type a/b or type b. exclusion criteria: all patients (adult and pediatric) * active serious intercurrent illness which will preclude enrollment, significant liver disease with etiology other than asmd, malignancy with poor prognosis, serious medical or psychiatric condition that may preclude participation, or circumstances that may interfere with compliance in this compassionate use program, requirement for recurrent dose adjustment of anticoagulation treatment over the last 6 months. * pregnancy or breastfeeding. * for female patients of childbearing potential, a positive serum pregnancy (β human chorionic gonadotropin \[hcg\]) test result. * for female patients of childbearing potential and sexually active male patients, unwillingness to abstain from heterosexual intercourse in accordance with their preferred and usual lifestyle, or to use 2 acceptable, effective contraceptive methods, while participating in this program and for 15 days after the last infusion of olipudase alfa. * for pediatric patients, clinical diagnosis, or suspicion of infantile onset asmd. genotype compatible with asmd type a.